Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
NCT05832541

Expression of Epithelial-Mesenchymal Transition Associated Markers in Peri-implant Tissues

Led by University of Baghdad · Updated on 2024-08-20

40

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Peri-implantitis is an inflammation of bacterial etiology characterized by inflammation of mucous membranes and bone loss around the dental implant. A specific dental plaque bacteria could stimulate host cells, including the junctional epithelium, to secrete a range of pro-inflammatory cytokines involved in initiating the epithelial-mesenchymal transition (EMT) process. EMT has been described as the transdifferentiation of epithelial cells into motile mesenchymal cells. Moreover, cytokines and bacterial products have been highlighted as EMT-predisposing factors. The EMT process could render epithelial cells to lose their cell-cell adhesion and cell polarity that lend these cells to lose their function as an integrated epithelial barrier. E-cadherin is a calcium-dependent cell adhesion molecule that establishes cell-cell adhesion that plays a critical role in maintaining a barrier function in the human epithelium, including gingiva. The loss of E-cadherin is one of the most common biological indicators for EMT. In contrast, vimentin is an intermediate filament expressed in mesenchymal cells and is a canonical marker for EMT, which also promotes cell motility and an invasive phenotype. It is largely reported that EMT is regulated by various transcriptional factors such as Snail Family Transcriptional Repressor SNAIL1 and SNAIL2, zinc-finger E-box-binding (ZEB)1 and ZEB2 and TWIST transcription factors that suppress epithelial marker genes, and activate genes related with the mesenchymal phenotype. Recently, in vivo study has investigated the level of EMT markers in the gingival tissues of periodontitis patients. It was found that the expression of E-cadherin was downregulated while vimentin expression was upregulated. Despite the similarities and differences between the pathogenesis of periodontal and peri-implant diseases, the role of dental biofilm in the etiopathogenesis of the aforementioned diseases was studied largely. While it is now accepted that EMT may potentially play a role in periodontal disease pathogenicity, the possible role of EMT in the disintegration of the peri-implant epithelial barrier and the pathogenesis of peri-implant disease has not yet been investigated.

CONDITIONS

Official Title

Expression of Epithelial-Mesenchymal Transition Associated Markers in Peri-implant Tissues

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients 18 years or older
  • For test group: have at least one dental implant in function for more than 12 months
  • Diagnosed with peri-implantitis showing probing pocket depth of 6 mm or more, bleeding on probing and/or suppuration
  • Radiographic bone loss compared to previous images or bone loss of 3 mm or more from the first implant thread
  • Visible signs of inflammation around the implant
  • For control group: adult patients 18 years or older with one or more missing adjacent teeth in the back of the upper or lower jaw
  • Adequate bone quality and volume for implant placement (diameter 4.5-5.0 mm, length 8.5-13 mm)
  • At least 3 mm width of keratinized gum tissue
  • Patients must provide written consent and attend planned follow-up visits
Not Eligible

You will not qualify if you...

  • For test group: history of chronic diseases such as diabetes mellitus
  • Currently smoking
  • Pregnant or breastfeeding women
  • Received peri-implant surgery within 6 months before tissue sampling
  • Received systemic or local antimicrobial therapy within 3 months before tissue sampling
  • For control group: medical conditions that prevent implant surgery
  • Presence of local inflammation including untreated periodontitis
  • Less than 6 weeks of healing after tooth extraction
  • Persistent oral infection
  • Absence of keratinized gum tissue
  • History of chronic diseases such as diabetes mellitus
  • Current or former smokers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Talib A. Alnajaty

Karbala, Iraq, 56001

Actively Recruiting

Loading map...

Research Team

T

Talib A Alnajaty

CONTACT

T

Talib A Alnajaty

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here